| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC2797 | Jar1.39 | Novel mitophagy inducer with therapeutic potential for Parkinson's disease, acting as light chain 3 (LC3) interactors, similar to cardiolipin or ceramide, triggering mitophagy via Pink1/Parkin |
|
| DCC2798 | jarid1b Demethylase Inhibitor | Novel Inhibitor of Jumonji AT-Rich Interactive Domain 1B (JARID1B) Histone Demethylase |
|
| DCC2799 | Jasminine | Natural naphthyridine alkaloid |
|
| DCC2800 | Jasplakinolide | Potent inhibitor of the proliferation of PC3 prostate carcinoma cells |
|
| DCC2801 | Jbir-22 | Natural Inhibitor for Protein−Protein Interaction of the Homodimer of Proteasome Assembly Factor 3 |
|
| DCC2802 | Jbir-59 | Natural radical scavenger, inhibiting L-glutamate toxicity in neuronal hybridoma N18-RE-105 cells |
|
| DCC2803 | Jbp485 | Inhibitor of renal transporters OAT1 and OAT3; Antihepatitis agent as a substrate for intestinal PEPT1 |
|
| DCC2804 | Jbp923 | Natural anti-inflammatory agent, showing potential for the treatment of inflammatory bowel disease (IBD) |
|
| DCC2805 | Jbsnf-000567 | Metabolite of JBSNF-000088 |
|
| DCC2806 | Jc1-40 | Novel RORα activator, diminishing diethylnitrosamine-induced acute liver injury and repressing transcriptional expression of APPs such as CXCL1 and LCN2 in mice |
|
| DCC2807 | Jcp-170 | Novel dose-dependent inhibitor of ABHD6 |
|
| DCC2808 | jcp174-alk | JCP174 analog used for affinity purification of labeled targets |
|
| DCC2809 | jcp174-ia | Negative control of JCP174 |
|
| DCC2810 | Jcp-265 | Novel dose-dependent inhibitor of ABHD6 |
|
| DCC2811 | Jcp405 | Covalent dual inhibitor of DPAP1 and DPAP3 |
|
| DCC2812 | Jcp410 | Covalent dual inhibitor of DPAP1 and DPAP3 |
|
| DCC2813 | Jcp474 | Novel potent inhibitor of Mpro |
|
| DCC2814 | Jcp678 | Novel irriversable serine hydrolases inhibitor |
|
| DCC2815 | jd-5006 | Peripheral Selective CB1 Receptor Antagonist |
|
| DCC2816 | Jesridonin | Novel apoptosis inducer, significantly inhibiting tumor growth in the xenograft model |
|
| DCC2817 | Jfd00950 | Novel human flap endonuclease 1 (FEN1) inhibitor with in vitro inhibition of flap cleavage activity as well as cytotoxic activity against a colon cancer cell line, DLD-1 |
|
| DCC2818 | Jg2-38 | Novel inhibitor of the heat shock protein 70 (Hsp70) with anti-proliferative activity in breast and prostate cancer cells |
|
| DCC2819 | Jh-i-17 | Novel type I Interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, binding preferentially to unphosphorylated IRAK4 |
|
| DCC2820 | Jh-i-25 | Novel Interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, binding preferentially to unphosphorylated IRAK4 |
|
| DCC2821 | Jk-136 | Novel Ras homologous A (RHOA) inhibitor, potently inhibiting cell viability and migration/invasion of gastric cancer (GC) cell lines, and mouse xenografts, diversely expressing RHOA, binding affinity for RHOA was >140-fold greater than Rhosin, a nonclinic |
|
| DCC2822 | Jk-31 (vegfr2/cdk1 Inhibitor) | Novel specific dual inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2) and cyclin-dependent kinase 1 (CDK1), targeting cell cycle progression and angiogenesis |
|
| DCC2823 | Jlj-334 | Potent non-nucleoside inhibitor of HIV-1 reverse transcriptase (NNRTIs) |
|
| DCC2824 | Jmv2951 | Novel potent GHS-R1a agonist (EC50 (Ca ): 1.6 nM), significantly stimulating GH secretion |
|
| DCC2825 | Jmv3168 | Novel ghrelin receptor (GHS-R1a) antagonist [IC 50 (affinity): 5 nM IC 50 (Ca ): 60 nM] |
|
| DCC2826 | Jmv4484 | Novel partial inverse agonist of GHS-R1a (K i = 3 nM, EC 50 = 70 nM, Emax = −37%) |
|
